The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.

As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.

Zhitong FinanceJul 22 06:50 ET

Roche Obesity-pill Trial Results Weigh on Shares of Eli Lilly, Novo Nordisk

MarketWatchJul 17 12:54 ET

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

Simply Wall StJul 15 09:39 ET

B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating

Moomoo NewsJul 12 11:31 ET · Ratings

These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey

Seeking AlphaJul 12 10:50 ET

This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment

Seeking AlphaJul 12 04:12 ET